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Objectives This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) pa-
tients receiving therapy with either bosentan or sildenafil.
Background There is no cure for PAH, despite effective treatments, and outcomes remain suboptimal. The addition of in-
haled treprostinil, a long-acting prostacyclin analog, might be a safe and effective treatment addition to other
PAH-specific oral therapies.
Methods Two hundred thirty-five PAH patients with New York Heart Association (NYHA) functional class III (98%) or IV
symptoms and a 6-min walk distance (6MWD) of 200 to 450 m while treated with bosentan (70%) or sildenafil
were randomized to inhaled treprostinil (up to 54 g) or inhaled placebo 4 times daily. The primary end point
was peak 6MWD at 12 weeks. Secondary end points included time to clinical worsening, Borg Dyspnea Score,
NYHA functional class, 12-week trough 6MWD, 6-week peak 6MWD, quality of life, and PAH signs and symp-
toms. The biomarker N-terminal pro-brain natriuretic peptide (NT-proBNP) was assessed.
Results Twenty-three patients withdrew from the study prematurely (13 treprostinil, 10 placebo). The Hodges-Lehmann
between-treatment median difference in change from baseline in peak 6MWD was 19 m at week 6 (p  0.0001)
and 20 m at week 12 (p  0.0004). Hodges-Lehmann between-treatment median difference in change from base-
line in trough 6MWD at week 12 was 14 m (p  0.0066). Quality of life measures and NT-proBNP improved on active
therapy. There were no improvements in other secondary end points, including time to clinical worsening, Borg Dys-
pnea Score, NYHA functional class, and PAH signs and symptoms. Inhaled treprostinil was safe and well-tolerated.
Conclusions This trial demonstrates that, among PAH patients who remain symptomatic on bosentan or sildenafil, inhaled
treprostinil improves exercise capacity and quality of life and is safe and well-tolerated. (TRIUMPH I: Double
Blind Placebo Controlled Clinical Investigation Into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in
Patients With Severe Pulmonary Arterial Hypertension; NCT00147199) (J Am Coll Cardiol 2010;55:1915–22)
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Inhaled Treprostinil for PAH May 4, 2010:1915–22Over the past 15 years, agents
from 3 therapeutic classes have
been investigated and are now
widely used for the treatment of
pulmonary arterial hypertension
(PAH), a rare disease character-
ized by progressive elevation in
pulmonary artery pressure, pul-
monary vascular resistance, and
ultimately, right ventricular fail-
ure (1,2). Prostacyclins (epopro-
stenol, treprostinil, and iloprost),
endothelin receptor antagonists
(bosentan, ambrisentan, and sitax-
sentan), and phosphodiesterase in-
hibitors (sildenafil, tadalafil) have
been evaluated in PAH patients,
on the basis of known pathobio-
logical mechanisms of action, and
ave demonstrated improvements in symptoms, exercise
olerance, and in some studies, hemodynamic status, over
he short term (3–9). There is no cure for PAH, despite
hese treatment options, and longer-term outcomes in PAH
ave been suboptimal. The concept of combining agents
argeting different pathways in an attempt to improve
utcomes is an area of active investigation, given the
vailability of agents from 3 distinct therapeutic categories.
o date, 4 randomized placebo-controlled trials of combi-
ation therapy are completed, with mixed results (10–13).
Treprostinil is a tricyclic benzindene prostacyclin analog,
ith pharmacologic actions similar to those of epoprostenol.
t is stable at room temperature and has an elimination
alf-life of 4.6 h (14). In a randomized, placebo-controlled
rial, treprostinil administered subcutaneously improved ex-
rcise capacity and hemodynamic status in PAH patients
4). Two small investigator-initiated open label studies have
uggested clinical benefit with treprostinil administered
ntravenously (15,16). Although clinically effective, subcu-
aneous and intravenous administration of treprostinil
ight be associated with adverse effects including infusion
ite pain and blood stream infections, respectively (17,18).
Initial open label studies with inhaled treprostinil have
emonstrated favorable effects in terms of exercise capacity
nd hemodynamic status (19,20). In this study (TRIUMPH
TReprostinil Sodium Inhalation Used in the Management
f Pulmonary Arterial Hypertension]), we assessed the
fficacy and safety of inhaled treprostinil or placebo in PAH
atients receiving therapy with either bosentan or sildenafil.
ethods
his was a 12-week, randomized, placebo-controlled,
ouble-blind, multicenter study in patients with PAH who
ere receiving a stable dose of bosentan or sildenafil for 3
onths before study initiation. The study was sponsored by
Abbreviations
and Acronyms
6MWD  6-min walk
distance
CI  confidence interval
eCMH  extended
Cochran-Mantel-Haenszel
H-L  Hodges-Lehmann
MLWHF  Minnesota
Living with Heart Failure
NT-proBNP  N-terminal
pro-brain natriuretic peptide
NYHA  New York Heart
Association
PAH  pulmonary arterial
hypertension
WRS  Wilcoxon rank sumnited Therapeutics Corporation. Following institutional 6eview board approval at each participating institution, all
atients provided written informed consent before any
tudy-related assessments.
Eligible patients were between the ages of 18 and 75 years
ith a confirmed diagnosis of idiopathic or familial PAH or
AH associated with collagen vascular disease, human
mmunodeficiency virus infection, or anorexigen use. Pa-
ients were New York Heart Association (NYHA) func-
ional class III or IV severity with a baseline 6-min walk
istance (6MWD) between 200 and 450 m and were
eceiving bosentan 125 mg daily or any prescribed dose of
ildenafil, 20 mg tid, for at least 3 months before study
ntry. Additionally, women of child-bearing potential were
equired to practice an acceptable method of birth control.
Patients were considered ineligible for study participation
f they: were pregnant or nursing; were diagnosed with any
cute or chronic illness other than those associated with
AH (collagen vascular disease, human immunodeficiency
irus, or anorexigen use); had received any investigational
edications, prostanoids, or phosphodiesterase inhibitors
ther than sildenafil within 30 days; or had changed or
iscontinued any PAH medication within 3 months.
Before randomization, patients were trained on proper
ebulizer technique with the OPTINEB device (Nebu-Tec,
lsenfeld, Germany). Patients were randomized (1 of 1) to
eceive either inhaled treprostinil sodium or placebo 4 times
aily in combination with bosentan or sildenafil. At the
iscretion of the study investigator, patients initiated ther-
py at 3 breaths (18 g)/inhalation. If clinically tolerated,
he dosing was to be increased over the first 2 weeks to reach
maximum of 9 breaths (54 g) at each of the 4 daily doses.
atients were contacted by study personnel via telephone to
ssess patient tolerance to study drug, adverse events, and to
p-titrate study drug dosing as tolerated.
Baseline, Week 6, and Week 12 assessments included
hysical exam including PAH signs and symptoms and vital
igns, NYHA functional classification, 6MWD, Borg Dys-
nea score (immediately after 6MWD), and clinical labo-
atory parameters including: urine pregnancy screening,
lood chemistries, hematology, coagulation times, and
-terminal pro-brain natriuretic peptide (NT-proBNP).
dditionally, at baseline and week 12, the following assess-
ents were conducted: complete medical history including
oncomitant medications, pulmonary function tests, chest
adiography, and completion of the Minnesota Living with
eart Failure (MLWHF) questionnaire. Adverse events
ere obtained throughout the study.
The primary end point was 6MWD measured at peak,
efined as within 10 to 60 min after treprostinil inhalation
t week 12. Secondary end points included time to clinical
orsening, defined as death, transplantation, hospital stay
ue to worsening PAH, or initiation of additional approved
AH-specific therapy, Borg Dyspnea Score, NYHA func-
ional class, trough 6 MWD at week 12 (obtained at least
h after study drug administration), peak 6MWD at Week, quality of life as measured by the MLWHF question-
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May 4, 2010:1915–22 Inhaled Treprostinil for PAHaire, and PAH signs and symptoms. The NT-pro BNP
as included as an ancillary assessment. All 6MWD assess-
ents were planned at 3 to 5 h after bosentan dosing or 30
o 120 min after sildenafil dosing.
tatistics. This study had 90% power to detect a 35-m
ifference (75-m SD) between treatment groups in peak
MWD change from Baseline at week 12 with at least 200
atients enrolled with power calculations in PASS software
Microsoft, Redmond, Washington) and a nonparametric
Mann-Whitney) adjustment to a 2-sample t test. This
ssumed SD was somewhat larger than that estimated from
he trial data (66.8 m), suggesting that the true power is
90%. For 6MWD variables including peak and trough, a
onparametric analysis of covariance was performed on all
andomized patients. The effect of inhaled treprostinil
ersus placebo on 6MWD was tested with nonparametric
nalysis of covariance within the framework of extended
ochran-Mantel-Haenszel (eCMH) test (21,22). Specifi-
ally, a Cochran-Mantel-Haenszel mean score test was used
n the standardized ranks of the residuals from an ordinary
east squares regression with change in 6MWD at week 12
s a linear function of etiology (as a categorical variable) and
aseline 6MWD (as a continuous variable). Etiology and
aseline 6MWD were chosen as covariates for this analysis,
ue to their demonstrated prognostic power in various
reviously conducted PAH trials. For confirmatory pur-
oses, the effect of inhaled treprostinil versus placebo on
MWD was further tested with the Wilcoxon rank sum
WRS) test. The median difference between treatment
roups was determined by the Hodges-Lehmann (H-L)
etween-treatment median difference. Imputation was used
or missing data with worst rank for death, addition of PAH
herapy during the trial or discontinuation due to disease
rogression, last rank carried forward for other missing
alues if a post-baseline assessment was performed, or the
ean of placebo ranks if there was no post-baseline
ssessment.
All secondary variables was evaluated by comparing the
ifference between baseline and week 12. The difference
etween treatment groups for baseline and secondary vari-
bles was evaluated with either a chi-square test (for
ichotomous data) or WRS test (for ordinal or continuous
ata).
The safety of inhaled treprostinil was evaluated by com-
aring adverse experiences in the 2 treatment groups with
egard to frequency, intensity, seriousness, and causality.
hanges in hematology, clinical chemistries, coagulation,
hest radiography, lung function tests, and vital signs from
aseline were also assessed between treatment groups.
esults
emographic data. Two hundred thirty-five patients with
mean age of 54 years (range 18 to 75 years) were enrolled
t 31 centers between June 2005 and July 2007. Patient
emographic data are described in Table 1. Of the 235
a
aatients, 115 were randomized to treprostinil and 120 were
andomized to placebo (Fig. 1). Twenty-three patients
ithdrew from the study prematurely, 13 (9 bosentan, 4
ildenafil) in the treprostinil group and 10 (8 bosentan, 2
ildenafil) in the placebo group. The mean dose of study
rug was 50  10 g in the inhaled treprostinil group and
2  7 g in the inhaled placebo group.
fficacy outcomes. 6-MIN WALK. The 6MWD results are
resented in Figures 2 and 3. The peak 6MWD within-
reatment median changes from baseline were 21.6 m
interquartile range: 8.0 to 54.0 m) and 3.0 m (inter-
uartile range: 26.0 to 31.5 m) for inhaled treprostinil
nd placebo groups, respectively, with an H-L between-
reatment median difference of 20 m at week 12 (95%
onfidence interval [CI]: 8.0 to 32.8, p[eCMH]  0.0004,
[WRS]  0.0016). The H-L between-treatment median
ifference in change in peak 6MWD was 19 m (95% CI: 8.5
o 28.3, p[eCMH]  0.0001, p[WRS]  0.0004) at Week
, and for the change in trough 6MWD it was 14 m (95%
I: 4 to 24.8, p[eCMH]  0.0066, p[WRS]  0.0040) at
eek 12. Patients in the lowest quartile for baseline 6MWD
204 to 302 m, n  59) had the greatest treatment effect in
hange in 6MWD by week 12, with an H-L between-
reatment median difference of 49 m (95% CI: 23.7 to 78.2,
[eCMH] 0.0003, p[WRS] 0.0007). As demonstrated
n Figure 3, 60 patients receiving inhaled treprostinil (52%)
xperienced an improved 6MWD of 20 m or greater, with
6 patients (31%) improving by at least 50 m. Patients
eceiving background bosentan therapy experienced an H-L
etween-treatment median difference in change in peak
MWD of 22 m (95% CI: 10.0 to 34.0, p[eCMH] 
.0001, p[WRS]  0.0004) and 25 m (95% CI: 10.2 to
0.0) p[eCMH]  0.0002, p[WRS]  0.0009) at weeks 6
nd 12, respectively. Patients taking sildenafil background
herapy had an H-L between-treatment median difference
atient Demographic DataTable 1 Patient Demographic Data
Characteristic
Inhaled TRE
(n  115)
Placebo
(n  120) p Value
Age, yrs 55 (20–75) 52 (18–75) 0.056
Male/female 22/93 22/98 0.88
PAH etiology
IPAH or familial 64 (56) 67 (56) 0.60
CVD 40 (35) 37 (31)
Other 11 (9) 16 (13)
Background PAH therapy
Bosentan 77 (67) 88 (73) 0.29
Sildenafil 38 (33) 32 (27)
Time on background therapy, weeks
Bosentan 99 79 90 75 0.62
Sildenafil 65 60 77 69 0.44
Baseline NYHA III/IV 112/3 118/2 0.62
Baseline 6MWD, m 346 63 351 69 0.50
alues are mean (range), n, n (%), or mean  SD.
6MWD  6-min walk distance; CVD  collagen vascular disease; IPAH  idiopathic pulmonary
rterial hypertension; NYHA  New York Heart Association functional class; PAH  pulmonary
rterial hypertension; TRE  treprostinil.
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Inhaled Treprostinil for PAH May 4, 2010:1915–22n change in peak 6MWD at weeks 6 and 12 of 11 and 9 m,
espectively (p  NS).
ECONDARY END POINTS. There was no difference in time
o clinical worsening between treatment groups (Table 2).
here was no change in Borg Dyspnea Score, NYHA
unctional classification, and PAH signs and symptoms
rom baseline to week 12 compared with placebo. Quality of
ife as assessed by the MLWHF questionnaire had an H-L
Overview of Patients Ent
Randomized
Allocated to receive inhaled Treprostinil (N=115) 
Received the allocated Intervention (N=115) 
Lost to Follow-up (N=0) 
Discontinued the Intervention (N=13) 
• Three patients with worsening PAH 
• Seven patients with Adverse Events 
• Three patients withdrew consent 
Analyzed for Efficacy, Intent to Treat (N=115) 
Analyzed for Safety (N=115) 
Figure 1 Patient Disposition
A total of 235 patients were randomized into the study—115 to treprostinil and 1
treprostinil/placebo. There were 13 premature discontinuations in the treprostinil
Figure 2 Change in 6MWD
Primary end point, change in peak 6-min walk distance (6MWD) for patient
receiving background sildenafil (ruled bars), background bosentan (dotted
bars), and the entire population (solid bars). There was a placebo-corrected
improvement of 20 m at 12 weeks in the total population. Results presented
as Hodges-Lehman between-treatment median difference.etween-treatment median difference of 4 in the global
core (p  0.027) and 2 in the physical score (p  0.037),
or patients receiving inhaled treprostinil.
NCILLARY END POINT. The NT-proBNP results are pre-
ented in Figure 4. One hundred fifty-five patients provided
ro-BNP results at baseline and week 12. Median baseline
T-proBNP levels were 593 pg/ml (n 73) and 670 pg/ml
n 82) in the treprostinil and placebo groups, respectively.
to the Trial 
35) 
Allocated to receive placebo (N=120) 
Received the allocated Intervention (N=120) 
Lost to Follow-up (N=0) 
Discontinued the Intervention (N=10) 
• One patient died 
• Four patients with Adverse Events 
• Five patients withdrew consent 
Analyzed for Efficacy, Intent to Treat (N=120) 
Analyzed for Safety (N=120) 
lacebo. All randomized patients received investigational
and 10 in the placebo group. PAH  pulmonary arterial hypertension.
Figure 3 6MWD Improvements
Distribution of the percentage of patients who achieved specific improvements
in 6-min walk distance (6MWD) at 12 weeks. For example, 31% of patients tak-
ing inhaled treprostinil and 12% of patients taking inhaled placebo had an
improvement in 6MWD of 50 m at 12 weeks.ered in
 (N=2
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May 4, 2010:1915–22 Inhaled Treprostinil for PAHhe NT-proBNP within treatment median changes from
aseline were 57 pg/ml (interquartile range: 396.0 to
4.0) and 40 pg/ml (interquartile range:93.0 to 288.0) for
nhaled treprostinil and placebo group, respectively, with an
-L between-treatment median difference in change from
aseline in NT-proBNP levels of 187 pg/ml (95% CI:
333 to 64.0, p  0.0014) at week 12. The H-L
etween-treatment median difference in change from base-
ine was159 pg/ml (95% CI:299 to64.0, p 0.0003)
t week 6.
afety. There were no clinically significant changes in
ulmonary function tests, chest radiography, or clinical
aboratory parameters, including: blood chemistries, hema-
ology, and coagulation times between treatment groups.
Seventy-five (72%) patients receiving inhaled treprostinil
nd 96 (87%) receiving placebo obtained the maximum dose
f 9 breaths (54 g) 4 times daily. The average time to
aximum dose was approximately 3 weeks in both treat-
ent groups.
Adverse events are summarized in Table 3. The most
ommon adverse event was cough, which occurred in 54%
f patients receiving inhaled treprostinil as compared with
-71
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Week 6 Baseline Pro-BNP (pg/mL): Week 12 Baseline Pro-BNP (pg/mL):
Placebo: median = 690 (n = 87)    Placebo: median = 670 (n = 82) 
Inhaled TRE: median = 602 (n = 86)   Inhaled TRE: median = 593 (n = 73) 
Figure 4 NT-proBNP Changes
Median change from baseline in N-terminal pro brain natriuretic peptide (NT-
proBNP) at week 6 and week 12. Samples were available for 155 patients at
week 12. TRE  treprostinil.
linical Worsening EventsTable 2 Clinical Worsening Events
Extent of Clinical Worsening
Treatment
Inhaled TRE
(n  115)
Placebo
(n  120)
No clinical worsening 111 (97) 114 (95)
Clinical worsening 4 (3) 6 (5)
Death 0 (0) 1 (1)
Transplantation 0 (0) 0 (0)
PAH hospital stay 4 (3) 5 (4)
Initiation of approved PAH therapy 0 (0) 0 (0)
alues shown are n (%).
PAH  pulmonary arterial hypertension; TRE  treprostinil.t9% of patients receiving placebo. There were 11 serious
dverse events reported in the inhaled treprostinil group,
ncluding 3 events of worsening pulmonary hypertension, 2
vents of syncope, and 1 event of each of the following:
nemia, abdominal pain, diabetes mellitus, diarrhea, gastric
lcer, and right ventricular failure.
Twenty-three patients prematurely discontinued the study.
n the placebo group, 1 patient died, 4 withdrew due to adverse
vents, and 5 patients withdrew consent; of these patients, 8
ere receiving background bosentan. In the inhaled treprostinil
roup, 3 patients discontinued due to worsening pulmonary
ypertension, 7 withdrew due to adverse events, and 3
ithdrew consent; of these patients, 9 were receiving back-
round bosentan.
iscussion
n this study, PAH patients with NYHA functional class III
r IV symptoms and a 6MWD of 200 to 450 m while
eceiving oral monotherapy with either bosentan or silde-
afil were randomized to receive either inhaled treprostinil
r placebo. The primary end point of change from baseline
n 6MWD at week 12 had an H-L between-treatment
edian difference of 20 m (p  0.0004). Additionally, the
hange in 6MWD improved as early as week 6 (H-L
edian difference of 19 m, p  0.0001) and was sustained
t trough at week 12 (14 m, p  0.0066). The importance
f sustained effects at trough is notable, because this is the
rst such observation with a prostanoid given on an inter-
ittent basis. The improvement in 6MWD was greatest in
hose in the lowest quartile for baseline 6MWD (49 m, p 
.0003). This observation of greatest benefit in the most
everely compromised patients studied was also made in the
ivotal trial with subcutaneous treprostinil but is contrary to
he recent study evaluating the addition of sildenafil in those
ymptomatic while receiving epoprostenol (4,12). The im-
rovement noted in these advanced but not end-stage
atients with inhaled treprostinil suggests that such patients
till have capacity to improve with inhaled prostanoid
dverse Events Occurring in10% of Patients Receiving Inhaled TRETable 3 Adverse Events Occurring in
>10% of Patients Receiving Inhaled TRE
Adverse Events Occurring
in >3% of TRE Patients
Treatment
Inhaled TRE (n  115) Placebo (n  120)
Cough 62 (54) 35 (29)*
Headache 47 (41) 27 (23)*
Nausea 22 (19) 13 (11)
Dizziness 20 (17) 18 (15)
Flushing 17 (15) 1 (1)*
Throat irritation 16 (14) 10 (8)
Pharyngolaryngeal pain 13 (11) 7 (6)
Diarrhea 11 (10) 9 (8)
alues shown are n (%). *p  0.05.
TRE  treprostinil.herapy.
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Inhaled Treprostinil for PAH May 4, 2010:1915–22Other observations, although not pre-specified analyses,
re worthy of comment. Twelve percent of the patients
andomized to placebo experienced an improvement in
MWD of more than 50 m at week 12, stressing the
mportance of placebo-controlled trials for PAH in which
he 6MWD is an end point. The improvement in 6MWD
as greater for patients receiving bosentan therapy com-
ared with sildenafil therapy, although the number of
atients taking sildenafil was smaller, and this comparison
as not an objective of this study. Although this improve-
ent in 6MWD is perhaps a function of sample size and
arying sildenafil dose, this observation is surprising, par-
icularly in light of the potential synergy between the cyclic
denosine monophosphate and cyclic guanosine monophos-
hate pathways and prior clinical reports with sildenafil and
rostanoids in both observational and controlled clinical
rials (12,23–25). More formal study of the combination of
nhaled treprostinil and oral sildenafil in an appropriately
owered trial would be informative.
The overall clinical worsening event rate in the study was
ow—only 10 total events. Clinical assessments, including
he 6MWD and NT-pro BNP, were static over the 12-
eek course of this trial in the placebo group, reflecting the
elative stability of this group over a short 12-week period,
otentially a function of the background therapy with
osentan or sildenafil. Although the definition of time to
linical worsening has varied from trial to trial, it has
unctioned as an important morbidity and mortality type
nd point in PAH trials. However, as clinical investigation
n PAH evolves, it is likely that trials will include those who
re less ill and already receiving PAH-specific therapy,
otentially resulting in low event rates as seen in the current
tudy. Trials of longer duration, ostensibly end point-driven
rials, might be the future direction of this field.
There were significant improvements in the secondary
nd point of quality of life as assessed by the MLWHF
uestionnaire and the ancillary end point of NT-pro BNP.
lasma NT-pro BNP concentrations correlate with hemo-
ynamic severity and prognosis in PAH (26–28). The
mprovement in NT-pro BNP with inhaled treprostinil in
his study was consistent with the improvements noted in
he placebo-controlled study of ambrisentan in PAH, the
nly other placebo-controlled trial that has evaluated NT-
ro BNP as an end point. The consistent NT-pro BNP in
he patients randomized to placebo is compelling and
uggests clinical stability over 12 weeks in this group of
atients treated with bosentan or sildenafil. Reductions in
T-pro BNP in patients treated with inhaled treprostinil
herapy for PAH might reflect a beneficial effect on right
entricular function and, in turn, prognosis.
Inhaled treprostinil was safe and well-tolerated. The most
ommon adverse event was cough, which occurred in 54%
nd 29% of the treprostinil and placebo groups, respectively.
ther commonly reported adverse events included head-
che, nausea, dizziness, and flushing—all common side
ffects of prostanoid therapy. rThis study compares favorably to other placebo-
ontrolled combination therapy trials. In the first ever
lacebo-controlled trial of combination therapy, Humbert
t al. (10) evaluated bosentan versus placebo in 33 patients
nitiating intravenous epoprostenol (upfront combination
herapy). There were improvements in functional class,
MWD, and hemodynamic status in both groups, but no
ifference between the groups. Although this is an
mportant study, due in part to the small sample size and
tudy design, the practical implications of this study are
imited.
Evaluating the addition of inhaled iloprost versus placebo
n PAH patients who remain symptomatic while taking
osentan has been the objective of 2 randomized placebo-
ontrolled trials. In 1, there was an improvement in post-
nhalation and pre-inhalation mean 6MWD of 26 m (p 
.051) and 19 m (p  0.14), respectively, as well as in
mprovement in time to clinical worsening (p  0.0219)
11). The other trial that evaluated the addition of
loprost or placebo to bosentan was terminated prema-
urely after a futility analysis predicted failure at the
redetermined sample size of 36 patients/group (13).
lthough the study design of these 2 studies parallel
urrent clinical practices, their application to contempo-
ary treatment is limited by the small sample size and the
ontradictory results. In comparison, the well-powered
urrent study demonstrates an effect on exercise capacity
s measured by the 6MWD both pre- and post-
nhalation at the conclusion of the study at 12 weeks and
fter inhalation as early as 6 weeks. On a practical note,
here is a patient-perceived advantage in the ease of
elivery with inhaled treprostinil compared with inhaled
loprost, which is administered 6 to 9 times/day with each
nhalation requiring on average 10 to 15 min.
In the largest placebo-controlled study of combination
herapy to date, Simonneau et al. (12) evaluated the addition
f sildenafil (target dose 80 mg tid) or placebo in 267 PAH
atients who remained symptomatic with a 6MWD of 100
o 450 m while taking a stable dose of intravenous epopro-
tenol for at least 3 months. These investigators reported an
mprovement in the placebo-adjusted mean 6MWD at 16
eeks of 28.8 m (p  0.0002) as well as improvements in
ulmonary artery pressure, cardiac output, and time to
linical worsening. Contrary to that of the current study, the
reatment benefit in terms of 6MWD was less impressive
or the patients with a lower baseline 6MWD. Again, given
he trial design, the practical implications of this study in
he current treatment paradigm, when many patients
ommence treatment with oral agents, is limited. Addi-
ionally, most patients were treated with sildenafil at a
ose of 80 mg tid, above the currently approved dose of
0 mg tid.
Compared with the other completed combination ther-
py trials, the current study is highly relevant in terms of
tudy design, adding a nonparenteral prostanoid in patients
eceiving initial oral therapy for PAH. Prostanoids have
l
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May 4, 2010:1915–22 Inhaled Treprostinil for PAHong been recognized as effective agents for the treatment of
AH. The complicated delivery system and potential side
ffects associated with parenteral prostanoids have deterred
ome patients and caregivers from instituting this effective
lass of agents early. The ease of delivery of inhaled
reprostinil, combined with the clinical benefits as demon-
trated here, might expand the prostanoid treatment options
or PAH patients.
Of note, all combination therapy trials completed to date
re of short duration (12 to 16 weeks) with a primary end
oint of 6MWD. The absolute magnitude of placebo-
orrected change in 6MWD in these trials is typically less
han many of the studies of monotherapy in treatment-naïve
atients. It is possible that the potential for further vasodi-
ation and antiremodeling with our current agents is blunted
fter a patient is exposed for some length of time to an agent
f another class. This underscores the importance of con-
inuing investigations into other agents with novel mecha-
isms of action in PAH.
tudy limitations. Limitations of this trial include the
xclusion of patients with less-severe disease, such as
hose with NYHA functional classes II symptoms or a
MWD 450 m. Although the entry criteria included
YHA functional classes III and IV, only 5 functional
lass IV patients were included, and thus the broad
pplicability to class IV patients is limited and should be
one with caution. Additionally, some types of PAH,
pecifically those associated with congenital heart disease
nd portal hypertension, were excluded. Although the
mprovements in all analyses related to the 6MWD were
tatistically significant, some of the other important
econdary end points—including time to clinical worsen-
ng and functional class— did not improve. Furthermore,
he trial was of only 12 weeks in duration, and longer-
erm observations would be clinically meaningful. Al-
hough the study was blinded and placebo-controlled,
ome of the side effects related to prostanoid therapy
headache, nausea, flushing), might have resulted in
nintentional unblinding in a minority of the patients.
hether similar results would have been obtained with
ther endothelin receptor antagonists, other phosphodi-
sterase inhibitors, or the combination of the 2 is
nknown. Lastly, although this study demonstrates in-
remental improvement in 6MWD with the addition of
nhaled treprostinil to bosentan or sildenafil therapy, it
oes not suggest a mechanism or elucidate the role of
ontinued therapy with bosentan or sildenafil. An addi-
ional arm mandating the withdrawal of bosentan or
ildenafil in patients randomized to inhaled treprostinil
ight have given insight to this issue.
onclusions
n summary, the addition of inhaled treprostinil in PAH
atients with NYHA functional classes III and IV symp-
oms while taking bosentan or sildenafil resulted in im-
1rovements in 6MWD at both peak and trough and was
afe and well-tolerated. Inhaled treprostinil has the poten-
ial to be an important addition to the treatment armamen-
arium for this serious disease.
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APPENDIX
or a list of members of the TRIUMPH Study Group,
lease see the online version of this article.
